Add a Comment By Memorial Sloan-Kettering   |   Friday, August 31, 2012 Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer. read more

Read the article:
Targeted Therapy for Advanced Prostate Cancer Receives FDA Approval